J&J: encouraging phase 1 results for Talvey

(CercleFinance.com) - On Friday, US healthcare giant Johnson & Johnson reported promising Phase 1 results for its new anti-cancer drug Talvey.


In a Phase 1b study, the antibody combined with Darzalex Faspro, another anti-cancer agent, achieved an overall response rate of 82% in patients with relapsed or refractory multiple myeloma.

J&J says that this result encourages the product's further development in this indication.

In another clinical trial, this time in relapsed or refractory multiple myeloma with extramedullary involvement and refractory to three classes of therapeutic agents, the response rate was 79.5%, the company says.

Since 2023 Talvey has been approved in the US for the treatment of relapsed or refractory multiple myeloma, although for patients who have received at least four previous lines of treatment.


Copyright (c) 2024 CercleFinance.com. All rights reserved.